Keiji Miyazawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Keiji Miyazawa has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Fumiaki Ito
The Institute of Prophylactic Pharmacology, Shinagawa, Tokyo 140-0001, Japan
1 shared publication Hiroyuki Miyoshi
BioResource Center, RIKEN, Tsukuba, Ibaragi 305‐0074, Japan
1 shared publication- Kenji Takeuchi
Department of Biochemistry, Faculty of Pharmaceutical Sciences, Setsunan University, Hirakata, Osaka, Japan
1 shared publication Kohei Miyazono
Department of Molecular Pathology, Graduate School of Medicine, University of Tokyo, Tokyo 113‐0033, Japan
1 shared publicationKouichiro Goto
Department of Molecular Pathology, Graduate School of Medicine, University of Tokyo, Tokyo 113‐0033, Japan
1 shared publication- Makio Hayakawa
School of Pharmacy, Tokyo University of Pharmacy and Life Science, 1432-1, Horinouchi, Hachioji, Tokyo 192-0392, JAPAN
1 shared publication
Latest Publications
- 12 October 2006
- Published by Wiley in Genes to Cells
- Vol. 11 (11) , 1267-1280
Nuclear and cytoplasmic c‐Ski differently modulate cellular functions
C‐Ski is a proto‐oncogene product that induces morphologic transformation, anchorage independence, and myogenic differentiation when it is over‐expressed in mesenchymal cells. c‐Ski also inhibits signaling of transforming growth factor‐β (TGF‐β) superfamily members through interaction with Smad proteins. Although c‐Ski is predominantly localized in the nucleus, aberrant cytoplasmic localization of it has also been reported in some tumor tissues and cell lines. In the present study, we identified the nuclear localization signal (NLS) in c‐Ski. By introducing a mutation to abolish NLS activity, we examined the function of cytoplasmic c‐Ski. Although cytoplasmic c‐Ski suppressed TGF‐β superfamily‐induced Smad signaling through sequestration of activated Smad complex to the cytoplasm, it failed to exhibit some of the activities that require nuclear localization of c‐Ski, including suppression of basal transcription of the Smad7 gene. These findings indicate that subcellular localization of c‐Ski affects its biologic activities. We also found that c‐Ski accumulated in the cytoplasm when proteasome activity was inhibited. Mapping of the regions required for cytoplasmic accumulation by proteasome inhibitors suggests that subcellular localization of c‐Ski may be regulated by proteasome‐sensitive processes through amino acid residues 94–210 and 491–548.
- 12 October 2006
- Published by Wiley in Genes to Cells
- Vol. 11 (11) , 1267-1280
Nuclear and cytoplasmic c‐Ski differently modulate cellular functions
C‐Ski is a proto‐oncogene product that induces morphologic transformation, anchorage independence, and myogenic differentiation when it is over‐expressed in mesenchymal cells. c‐Ski also inhibits signaling of transforming growth factor‐β (TGF‐β) superfamily members through interaction with Smad proteins. Although c‐Ski is predominantly localized in the nucleus, aberrant cytoplasmic localization of it has also been reported in some tumor tissues and cell lines. In the present study, we identified the nuclear localization signal (NLS) in c‐Ski. By introducing a mutation to abolish NLS activity, we examined the function of cytoplasmic c‐Ski. Although cytoplasmic c‐Ski suppressed TGF‐β superfamily‐induced Smad signaling through sequestration of activated Smad complex to the cytoplasm, it failed to exhibit some of the activities that require nuclear localization of c‐Ski, including suppression of basal transcription of the Smad7 gene. These findings indicate that subcellular localization of c‐Ski affects its biologic activities. We also found that c‐Ski accumulated in the cytoplasm when proteasome activity was inhibited. Mapping of the regions required for cytoplasmic accumulation by proteasome inhibitors suggests that subcellular localization of c‐Ski may be regulated by proteasome‐sensitive processes through amino acid residues 94–210 and 491–548.
- Open Access
- 12 November 1993
- Published by Wiley in FEBS Letters
- Vol. 334 (3) , 331-334
Stimulation of prostaglandin production by hepatocyte growth factor in human gastric carcinoma cells
Hepatocyte growth factor (HGF), a protein with pleiotropic biological activity affecting cell growth and motility, was found to markedly activate prostaglandin production in human gastric carcinoma TMK‐1 cells. HPLC analysis revealed that HGF stimulated the production of prostaglandin E2 (PGE2), which is the major prostaglandin produced in these cells. HGF maximally stimulated PGE2 production at a concentration of 10 , and it was a more potent stimulator of PGE2 production than epidermal growth factor (EGF), which is known to stimulate prostaglandin production in various cell lines. The simultaneous addition of HGF and EGF caused no further stimulation of the PGE2 production observed in HGF‐treated cells. We showed also that HGF increased the arachidonate release from TMK‐1 cells, which release was completely suppressed by the addition of phospholipase A2 (PLA2) inhibitors. Further studies in vitro showed that HGF enhanced cellular activities of cytosolic PLA2 and cyclooxygenase 1.5‐fold each. These results indicate that HGF stimulates prostaglandin production through increases in both cytosolic PLA2 and cyclooxygenase activities.
- 12 November 1993
- Published by Wiley in FEBS Letters
- Vol. 334 (3) , 331-334
Open AccessStimulation of prostaglandin production by hepatocyte growth factor in human gastric carcinoma cells
Hepatocyte growth factor (HGF), a protein with pleiotropic biological activity affecting cell growth and motility, was found to markedly activate prostaglandin production in human gastric carcinoma TMK‐1 cells. HPLC analysis revealed that HGF stimulated the production of prostaglandin E2 (PGE2), which is the major prostaglandin produced in these cells. HGF maximally stimulated PGE2 production at a concentration of 10 , and it was a more potent stimulator of PGE2 production than epidermal growth factor (EGF), which is known to stimulate prostaglandin production in various cell lines. The simultaneous addition of HGF and EGF caused no further stimulation of the PGE2 production observed in HGF‐treated cells. We showed also that HGF increased the arachidonate release from TMK‐1 cells, which release was completely suppressed by the addition of phospholipase A2 (PLA2) inhibitors. Further studies in vitro showed that HGF enhanced cellular activities of cytosolic PLA2 and cyclooxygenase 1.5‐fold each. These results indicate that HGF stimulates prostaglandin production through increases in both cytosolic PLA2 and cyclooxygenase activities.